Get the Stockscreener App
0.00
100.00%
-12.00
Finch Therapeutics Group Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$12.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$107.00K
Net Income/Loss:
$-14.17M
P/E Ratio:
0.00
EPS:
-8.8233
Net Cash Flow:
$-18.04M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
+245.37%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$14.75
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Name
Finch Therapeutics Group Inc
Sector
Industry
Phone
-
Address
-
Compare FNCH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FNCH
Finch Therapeutics Group Inc
|
0.00 | 0 | 107.00K | -14.17M | -18.04M | -8.8233 |
VRTX
Vertex Pharmaceuticals Inc
|
427.16 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.69 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
786.34 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.42 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.25 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-22 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | BofA Securities | Buy |
| Apr-13-21 | Initiated | Evercore ISI | Outperform |
| Apr-13-21 | Initiated | Jefferies | Buy |
Finch Therapeutics Group Inc Stock (FNCH) Latest News
Finch Therapeutics: We Will Get A Healthy Premium (FNCHQ) - Seeking Alpha
Clostridium Difficile Infections Pipeline Set - openPR.com
Microbiome Therapeutics Market is Going to Booming Growth - openPR.com
Fecal Microbiota Transplantation (FMT) Market Overview, Key Trends, and Major Player Analysis - openPR.com
Global Factors Influencing the Rapid Evolution of the Difficile-Associated Diarrhea Treatment Market - openPR.com
Autism Spectrum Disorder Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Finch Therapeutics Group Inc (FNCH) - Minichart
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Finch Therapeutics Gr Stock Short Interest Report | OTC:FNCHQ - Benzinga
Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart
Clostridium Difficile Infections Treatment Pipeline Shows - openPR.com
Price Performance - Yahoo! Finance Canada
Finch Therapeutics Group, Inc. (FNCHQ) Insider Ownership & Holdings - Yahoo! Finance Canada
Finch Therapeutics Group, Inc. (FNCHQ) Balance Sheet - Yahoo! Finance Canada
Finch Therapeutics Group, Inc. (FNCHQ) Income Statement - Yahoo! Finance Canada
What date does Finch Therapeutics Group's (FNCHQ) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
FNCHQ: Finch Therapeutics GroupComparative Chart - Zacks Investment Research
Dividend HistoryFinch Therapeutics Group (FNCHQ) - Zacks Investment Research
What is the current Price Target and Forecast for Finch Therapeutics Group (FNCHQ) - Zacks Investment Research
Finch Therapeutics Group (FNCHQ) Total Assets (Quarterly) - Zacks Investment Research
Finch Therapeutics Group (FNCHQ) Revenue (Quarterly) - Zacks Investment Research
Finch Therapeutics Group (FNCHQ) Return On Assets (TTM) - Zacks Investment Research
Return on invested capital % of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Price to book ratio of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Discontinued operations of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Diluted shares outstanding of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Long term debt to total equity ratio of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
FNCHQ : Finch Therapeutics Group Key Company Details - Zacks Investment Research
Finch Therapeutics Group, Inc. Balance Sheet – OTC:FNCHQ - TradingView
Finch Therapeutics Group, Inc. Statistics – OTC:FNCHQ - TradingView
Return on assets % of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Finch Therapeutics Group, Inc. Cash Flow – OTC:FNCHQ - TradingView
Operating cash flow per share of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Finch Therapeutics Group, Inc. Earnings and Revenue – OTC:FNCHQ - TradingView — Track All Markets
Finch Therapeutics Group, Inc. Income Statement – OTC:FNCHQ - TradingView
Finch Therapeutics Group, Inc. Financial Statements – OTC:FNCHQ - TradingView
Finch Therapeutics Group (FNCHQ) Return On Equity (TTM) - Zacks Investment Research
Technical Analysis of Finch Therapeutics Group, Inc. (OTC:FNCHQ) - TradingView
Basic earnings per share (basic EPS) of Finch Therapeutics Group, Inc. – OTC:FNCHQ - TradingView
Finch Therapeutics Group (FNCHQ) Gross Profit (TTM) - Zacks Investment Research
Finch Therapeutics Group (FNCHQ) Cash From Operations (TTM) - Zacks Investment Research
Finch Therapeutics Group (FNCH) Expected to Announce Quarterly Earnings on Friday - Defense World
FNCHQ Stock Price and Chart — OTC:FNCHQ - TradingView
Finch Therapeutics Group (FNCHQ) Net Income (TTM) - Zacks Investment Research
All News for FNCHQ : Finch Therapeutics Group - Zacks Investment Research
FNCHQ (Finch Therapeutics Group) PB Ratio : 0.97 (As of Mar. 26, 2026) - GuruFocus
Meet The Attys In Biotech Biz Finch's Ch. 11 - Law360
Fecal Treatment Co. Says Ch. 11 Is Best Option To Sell Assets - Law360
Finch Therapeutics Group (FNCHQ) Pe Ratio (TTM) - Zacks Investment Research
Catching Up With New Bankruptcy Case Action - Law360
Fecal Treatment Co. Files Ch. 11 To Escape Lease, Sell IP - Law360
Finch Therapeutics Group Inc Stock (FNCH) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.78%
0.81%
Cap:
|
Volume (24h):